Alzheimers disease
Conditions
Interventions
Non-dementia other neurological disease group:None
Healthy control group:None
Sponsors
The First Hospital of Lanzhou University
Eligibility
Sex/Gender
All
Age
40 Years to 85 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for the cognitive impairment group: 1.Outpatients and inpatients from the neurology and geriatrics departments of 3 tertiary grade A hospitals; 2.Age 40-85 years (inclusive of 40 and 85 years), gender not limited; 3.Confirmed diagnosis of Alzheimer's disease (AD), vascular cognitive impairment (VCI), Lewy body dementia (DLB), Parkinson's disease dementia (PDD), frontotemporal lobar degeneration (FTLD), or other types of dementia; 4.Voluntary participation in this study and signing of the informed consent form. Inclusion criteria for the non-cognitive impairment other diseases group: 1.Outpatients and inpatients from the neurology and geriatrics departments of 3 tertiary grade A hospitals; 2.Age 40-85 years (inclusive of 40 and 85 years), gender not limited; 3.Normal cognitive function; 4.Confirmed diagnosis of one of the following diseases: neurodegenerative diseases (Parkinson's disease, vascular Parkinsonism syndrome, multiple system atrophy, progressive supranuclear palsy, motor neuron disease), cerebrovascular diseases (acute cerebral infarction, acute cerebral hemorrhage, subarachnoid hemorrhage, non-acute large area cerebral infarction), neuroimmune diseases (multiple sclerosis, neuromyelitis optica spectrum disorder, myasthenia gravis), peripheral nerve diseases (Guillain-Barré syndrome), infectious encephalitis/meningitis, autoimmune encephalitis, current syphilis infection, vitamin B12 deficiency-related neurological diseases; Inclusion criteria for the healthy control group: 5. Voluntary participation in this study and signing of the informed consent form. 1.No neurological diseases; 2.Normal cognitive function; 3.Reside in the same area as the case group; 4.Aged 40-85 years (inclusive of 40 and 85 years), no gender restrictions; 5. Voluntarily participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Mixed dementia; 2.Patients with AD who received lenalidomide treatment; 3.Patients with severe heart, lung, liver, kidney or blood system diseases, or those with concurrent tumors; 4.Refused to have blood drawn; 5. Refused to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aß 40;Aß 42;Phosphorylated Tau 181;Phosphorylated Tau 217;Phosphorylated Tau 231;Glial Fibrillary Acidic Protein;Neurofilament Light; | — |
Countries
China
Contacts
Public ContactHaitao Yu
The First Hospital of Lanzhou University
Outcome results
None listed